METASTATIC NON-SMALL CELL LUNG CANCER WITH MTAP DELETION

Clinical trials for METASTATIC NON-SMALL CELL LUNG CANCER WITH MTAP DELETION explained in plain language.

Never miss a new study

Get alerted when new METASTATIC NON-SMALL CELL LUNG CANCER WITH MTAP DELETION trials appear

Sign up with your email to follow new studies for METASTATIC NON-SMALL CELL LUNG CANCER WITH MTAP DELETION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Breakthrough trial targets genetic weakness in aggressive lung cancer

Disease control Recruiting now

This study is testing whether adding an experimental drug called BMS-986504 to standard immunotherapy and chemotherapy works better than standard treatment alone for people with advanced lung cancer that has spread and has a specific genetic deletion called MTAP. The trial will i…

Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER WITH MTAP DELETION

Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control

Last updated Mar 18, 2026 14:40 UTC

METASTATIC NON-SMALL CELL LUNG CANCER WITH MTAP DELETION

Get alerted when new METASTATIC NON-SMALL CELL LUNG CANCER WITH MTAP DELETION trials appear

Breakthrough trial targets genetic weakness in aggressive lung cancer